Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.

Min Kyung ParkYun Bin LeeHyemi MoonNa Ryung ChoiMinseok Albert KimHeejoon JangJoon Yeul NamEun Ju ChoJeong-Hoon LeeSu Jong YuYoon Jun KimJung-Hwan Yoon

Published in: Digestive diseases and sciences (2022)

The effectiveness of lenvatinib and sorafenib was comparable for the treatment of unresectable HCC in decompensated patients.

Keyphrases

ejection fraction
randomized controlled trial
end stage renal disease
systematic review
heart failure
newly diagnosed
locally advanced
chronic kidney disease
liver metastases
radiation therapy
rectal cancer